http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
-
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
-
Praxis reports positive seizure reduction results from vormatrigine trial
-
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
-
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
-
Praxis receives FDA breakthrough therapy designation for relutrigine
-
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines to Participate in Upcoming Conferences
-
Praxis Precision Medicines (PRAX) Highlights DEE Clinical Program Updates at Virtual Investor Event
-
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
-
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
-
Praxis Precision Medicines to Participate in Upcoming April Conferences
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
-
Praxis Precision Medicines (PRAX) announces inducement grants
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
-
Praxis Precision Medicines (PRAX) IDMC has recommended Essential3 study be stopped for futility
-
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines to Present at Two February Investor Conferences
-
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
-
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
-
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
-
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
-
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
-
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
-
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
-
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
-
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
-
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
-
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
-
Praxis Precision Medicines (PRAX) announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
-
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
-
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
-
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
-
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
-
Praxis Precision Medicines to Participate in Upcoming April Conferences
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines (PRAX) Reports Positive Results of PRAX-628 Study
